First Health Pharmaceuticals is proud to be part of AVITHRAPID, the European Community funded public-private consortium for preparedness against potential pandemic viruses. Viral diseases represent…
RNA Viruses
Besides our Research and Development in The Netherlands, First Health Pharmaceuticals has important collaborations worldwide, especially in countries such as India and Italy. Recently we…
First Health Pharmaceuticals has been investigating the activity of its compounds on the replication of various RNA viruses, therefore, no wonder that we have also…
Clinically-validated nasal airway epithelial cell models for COVID-19 high throughput drug development As the unparalleled global health crises caused by the novel coronavirus SARS-CoV-2 seems…
A few days after the coronavirus disease 2019 (CoViD-19) outbreak turned out to be a pandemic, all of a sudden it became necessary to tackle…
The spread of novel coronavirus in China has been confirmed by Chinese authorities. After more than 290 sickened people and presumably more than 1700 infected…
Global HIV & AIDS figures According to the latest global statistics on the status of AIDS epidemic, in 2016, 36.7 million people were living with…
Today it was announced that the use of the only approved Dengue vaccine, Dengvaxia, is to be strictly limited due to evidence it can worsen…
The DDX3 RNA Helicase is a known host factor for a wide array of viruses of which many are already investigated by our group. Some…
Besides investigating and optimising the efficacy, toxicity and deliverability of our antiviral compounds, we also started three closely related research projects. One focuses on the…